BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34245124)

  • 1. Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities.
    Mahdi H; Joehlin-Price A; Elishaev E; Dowlati A; Abbas A
    Mol Oncol; 2021 Dec; 15(12):3545-3558. PubMed ID: 34245124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
    Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
    Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma.
    Horie M; Tanaka H; Suzuki M; Sato Y; Takata S; Takai E; Miyashita N; Saito A; Nakatani Y; Yachida S
    Cancer Sci; 2023 Jun; 114(6):2596-2608. PubMed ID: 36840413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Origins, genetic landscape, and emerging therapies of small cell lung cancer.
    Semenova EA; Nagel R; Berns A
    Genes Dev; 2015 Jul; 29(14):1447-62. PubMed ID: 26220992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated cellular and molecular model of gastric neuroendocrine cancer evolution highlights therapeutic targets.
    Griger J; Widholz SA; Jesinghaus M; de Andrade Krätzig N; Lange S; Engleitner T; Montero JJ; Zhigalova E; Öllinger R; Suresh V; Winkler W; Lier S; Baranov O; Trozzo R; Ben Khaled N; Chakraborty S; Yu J; Konukiewitz B; Steiger K; Pfarr N; Rajput A; Sailer D; Keller G; Schirmacher P; Röcken C; Fagerstedt KW; Mayerle J; Schmidt-Supprian M; Schneider G; Weichert W; Calado DP; Sommermann T; Klöppel G; Rajewsky K; Saur D; Rad R
    Cancer Cell; 2023 Jul; 41(7):1327-1344.e10. PubMed ID: 37352862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden.
    Kang NW; Tan KT; Li CF; Kuo YH
    Curr Oncol; 2021 Nov; 28(6):4587-4596. PubMed ID: 34898561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
    Cimic A; Vranic S; Arguello D; Contreras E; Gatalica Z; Swensen J
    Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):299-304. PubMed ID: 33208671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.
    Zhang J; Chen H; Zhang J; Wang S; Guan Y; Gu W; Li J; Zhang X; Li J; Wang X; Lu Z; Zhou J; Peng Z; Sun Y; Shao Y; Shen L; Zhuo M; Lu M
    Chin J Cancer Res; 2024 Feb; 36(1):90-102. PubMed ID: 38455367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.
    Frizziero M; Kilgour E; Simpson KL; Rothwell DG; Moore DA; Frese KK; Galvin M; Lamarca A; Hubner RA; Valle JW; McNamara MG; Dive C
    Clin Cancer Res; 2022 May; 28(10):1999-2019. PubMed ID: 35091446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma.
    Zhou Z; Zhu L; Niu X; Shen S; Zhao Y; Zhang J; Ye J; Han-Zhang H; Liu J; Liu C; Lu S
    Thorac Cancer; 2019 Apr; 10(4):839-847. PubMed ID: 30793508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
    Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
    Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.
    George J; Walter V; Peifer M; Alexandrov LB; Seidel D; Leenders F; Maas L; Müller C; Dahmen I; Delhomme TM; Ardin M; Leblay N; Byrnes G; Sun R; De Reynies A; McLeer-Florin A; Bosco G; Malchers F; Menon R; Altmüller J; Becker C; Nürnberg P; Achter V; Lang U; Schneider PM; Bogus M; Soloway MG; Wilkerson MD; Cun Y; McKay JD; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Lemaitre N; Soltermann A; Weder W; Tischler V; Brustugun OT; Lund-Iversen M; Helland Å; Solberg S; Ansén S; Wright G; Solomon B; Roz L; Pastorino U; Petersen I; Clement JH; Sänger J; Wolf J; Vingron M; Zander T; Perner S; Travis WD; Haas SA; Olivier M; Foll M; Büttner R; Hayes DN; Brambilla E; Fernandez-Cuesta L; Thomas RK
    Nat Commun; 2018 Mar; 9(1):1048. PubMed ID: 29535388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiles of small cell lung cancer.
    George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
    Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
    Kawai H; Matsuoka R; Ito T; Matsubara D
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma.
    Peng YP; Liu QD; Lin YJ; Peng SL; Wang R; Xu XW; Wei W; Zhong GH; Zhou YL; Zhang YQ; Liu Y; Wang SY; Hong HY; Liu ZG
    Radiat Oncol; 2021 Oct; 16(1):198. PubMed ID: 34635145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
    Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
    Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
    Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.
    Dasari A; Mehta K; Byers LA; Sorbye H; Yao JC
    Cancer; 2018 Feb; 124(4):807-815. PubMed ID: 29211313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.